Oculis Holding AG (NASDAQ:OCS) Given Consensus Rating of “Moderate Buy” by Analysts

Oculis Holding AG (NASDAQ:OCS) has received a consensus recommendation of “Moderate Buy” from the seven brokerages that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $42.3333.

A number of equities analysts have recently weighed in on OCS shares. Wall Street Zen raised shares of Oculis from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Needham & Company LLC reissued a “buy” rating and set a $36.00 price objective on shares of Oculis in a report on Tuesday, November 11th. HC Wainwright upped their target price on shares of Oculis from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a research report on Wednesday, October 8th. Finally, Lifesci Capital assumed coverage on Oculis in a research note on Wednesday, December 3rd. They set an “outperform” rating and a $55.00 price target on the stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Bosun Asset Management LLC acquired a new position in shares of Oculis during the 2nd quarter worth $378,000. Marshall Wace LLP purchased a new position in Oculis during the 2nd quarter valued at about $393,000. Geode Capital Management LLC increased its holdings in Oculis by 27.7% during the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after acquiring an additional 6,384 shares in the last quarter. Bank of America Corp DE raised its position in Oculis by 2.2% during the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after acquiring an additional 878 shares during the last quarter. Finally, Woodline Partners LP lifted its holdings in shares of Oculis by 65.8% in the third quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock valued at $1,474,000 after purchasing an additional 33,265 shares in the last quarter. Hedge funds and other institutional investors own 22.30% of the company’s stock.

Oculis Stock Performance

Shares of OCS stock opened at $19.84 on Wednesday. The company has a current ratio of 4.47, a quick ratio of 4.47 and a debt-to-equity ratio of 0.02. The stock has a 50 day simple moving average of $20.14 and a 200-day simple moving average of $18.84. The company has a market cap of $1.04 billion, a price-to-earnings ratio of -7.87 and a beta of 0.32. Oculis has a 12-month low of $14.00 and a 12-month high of $23.08.

Oculis (NASDAQ:OCS) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.10. The firm had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.23 million. Oculis had a negative return on equity of 80.82% and a negative net margin of 12,915.42%. On average, equities analysts forecast that Oculis will post -2.09 EPS for the current year.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.